- ICH GCP
- US-Register für klinische Studien
- Klinische Studie NCT07809022
Temporary Tear Duct Filling With Hyaluronic Acid Gel and Assessment of Dry Eye Disease (DED) After Bilateral Cataract Surgery (TANAMI)
Temporary Tear Duct Filling With Hyaluronic Acid Gel and Assessment of Dry Eye Disease (DED) After Bilateral Cataract Surgery in a Prospective Randomized Controlled Inter-eye Study
Dry eye disease can occur or worsen after cataract surgery and may cause ocular discomfort and reduced visual quality. Standard treatment commonly includes artificial tear eye drops, which provide temporary lubrication. Temporary occlusion of the tear drainage system may offer an alternative approach by increasing tear retention and improving tear film stability.
This prospective, randomized, double-blind, inter-eye study will evaluate the use of LACRIFILL® Canalicular Gel, a crosslinked hyaluronic acid gel placed in the tear drainage system, in patients who have undergone bilateral cataract surgery. Treatment allocation will be randomized at the eye level within each participant. One eye will be assigned to treatment with LACRIFILL®, while the fellow eye will serve as the control and receive standard care with artificial tear eye drops.
The study will compare the development and severity of dry eye disease between the randomized treatment and control eyes. The main outcome will be tear production measured by the Schirmer Test 1 one month after treatment. Additional assessments will include tear film stability, ocular surface findings, anterior segment imaging, visual quality, dry eye symptoms, use of artificial tears, and treatment-related safety outcomes during a three-month follow-up period.
Studienübersicht
Status
Intervention / Behandlung
Studientyp
Einschreibung (Geschätzt)
Phase
- Phase 4
Kontakte und Standorte
Studienorte
-
-
State of Vienna
-
Vienna, State of Vienna, Österreich, 1090
- Medical University of Vienna, Department of Ophthalmology and Optometry
-
Kontakt:
- Gregor S. Reiter, MD, PhD, BA, MSc
- Telefonnummer: +43 1 40400 73419
- E-Mail: gregor.reiter@meduniwien.ac.at
-
Kontakt:
- Johannes Schrittwieser, MD
- Telefonnummer: +43 1 40400 73557
- E-Mail: johannes.schrittwieser@meduniwien.ac.at
-
Hauptermittler:
- Gregor S. Reiter, MD, PhD, BA, MSc
-
Unterermittler:
- Johannes Schrittwieser, MD
-
Unterermittler:
- Markus Schranz, MD
-
-
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
- Erwachsene
- Älterer Erwachsener
Akzeptiert gesunde Freiwillige
Beschreibung
Inclusion Criteria:
- Uncomplicated bilateral cataract surgery for age-related cataract within the last 2-7 days
- Implantation of the same type of lens in both eyes (diopters may differ).
- Age 45-99 years
- Willingness to complete the study
- Signed informed consent form
Exclusion Criteria:
- Bilateral cataract due to a different cause
- Retinal findings affecting quality of life or visual acuity in any eye
- History of uncontrolled glaucoma in any eye (defined as intraocular pressure ≥ 25 mmHg despite treatment with anti-glaucoma mediation)
- Active or suspected ocular or periocular infection in the study eye.
- Vitreous hemorrhage or history of rhegmatogenous retinal detachment or macular hole in the study eye.
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Behandlung
- Zuteilung: Zufällig
- Interventionsmodell: Parallele Zuordnung
- Maskierung: Doppelt
Waffen und Interventionen
Teilnehmergruppe / Arm |
Intervention / Behandlung |
|---|---|
|
Experimental: LACRIFILL® Canalicular Gel Lacrimal Occlusion
Within each participant, one eye will be randomly assigned to receive a single intracanalicular administration of LACRIFILL® Canalicular Gel into the lower canaliculus.
The intervention is intended to provide temporary occlusion of the lacrimal drainage system and thereby reduce tear drainage and increase tear retention.
The fellow eye will serve as the control eye.
|
LACRIFILL® Canalicular Gel is a crosslinked hyaluronic acid hydrogel administered intracanalicularly into the lower canaliculus.
Approximately 0.2 mL is administered as a single application to the randomized treatment eye to achieve temporary occlusion of the lacrimal drainage system.
|
|
Schein-Komparator: Lacrimal Irrigation
The fellow eye of each participant will undergo lacrimal irrigation as a sham procedure.
No LACRIFILL® Canalicular Gel will be administered to the control eye.
The control eye will otherwise receive standard postoperative care, including artificial tear supplementation, according to standard clinical practice.
|
Lacrimal irrigation performed as a sham procedure in the control eye without administration of LACRIFILL® Canalicular Gel or temporary canalicular occlusion.
|
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Inter-eye difference in Schirmer Test 1 at month 1
Zeitfenster: 1 months
|
Difference in Schirmer Test I tear production between the Lacrifill-treated eye and the contralateral standard-of-care eye at 1 month after cataract surgery.
Schirmer Test I measures tear production as the length of wetting of a standardized filter paper strip over 5 minutes, expressed in millimeters (mm).
Values for each eye range from 0 to 35 mm, with higher values indicating greater tear production.
The inter-eye difference is calculated as the Schirmer Test I value in the Lacrifill-treated eye minus the value in the standard-of-care eye, resulting in a possible range of -35 to +35 mm.
Positive values indicate greater tear production in the Lacrifill-treated eye.
|
1 months
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Inter-eye difference in Schirmers Test 1 at month 3
Zeitfenster: 3 Months
|
Difference in Schirmer Test I tear production between the Lacrifill-treated eye and the contralateral standard-of-care eye at 3 month after cataract surgery.
Schirmer Test I measures tear production as the length of wetting of a standardized filter paper strip over 5 minutes, expressed in millimeters (mm).
Values for each eye range from 0 to 35 mm, with higher values indicating greater tear production.
The inter-eye difference is calculated as the Schirmer Test I value in the Lacrifill-treated eye minus the value in the standard-of-care eye, resulting in a possible range of -35 to +35 mm.
Positive values indicate greater tear production in the Lacrifill-treated eye.
|
3 Months
|
|
Inter-eye difference in Oxford grading at month 1 and months 3
Zeitfenster: 1 month, 3 months
|
Difference in ocular surface staining between the Lacrifill-treated eye and the contralateral standard-of-care eye at 1 and 3 months after cataract surgery, assessed using the Oxford Scheme for Ocular Surface Staining.
The Oxford score ranges from 0 to 5 for each eye, with higher scores indicating greater ocular surface staining and therefore a worse outcome.
The inter-eye difference is calculated as the Oxford score in the Lacrifill-treated eye minus the score in the standard-of-care eye, resulting in a possible range of -5 to +5.
Negative values indicate less ocular surface staining, and therefore a better outcome, in the Lacrifill-treated eye.
|
1 month, 3 months
|
|
Inter-eye difference in tear break up time (TBUT) at month 1 and 3
Zeitfenster: 1 month; 3 months
|
Difference in Tear Film Break-Up Time (TBUT) between the Lacrifill-treated eye and the contralateral standard-of-care eye at 1 and 3 months after cataract surgery.
TBUT is measured in seconds and represents the time between a complete blink and the first appearance of a break in the tear film.
Higher TBUT values indicate greater tear film stability and therefore a better outcome.
The inter-eye difference is calculated as the TBUT in the Lacrifill-treated eye minus the TBUT in the standard-of-care eye; positive values indicate greater tear film stability in the Lacrifill-treated eye.
|
1 month; 3 months
|
|
Non-invasive tear break-up time measured with the MS-39 at Months 1 and 3
Zeitfenster: 1 month; 3 months
|
Tear film stability will be assessed using the first non-invasive tear break-up time (NIBUT) measured with the MS-39 anterior segment analyzer (CSO, Florence, Italy).
The integrated Placido disk-based tear film analysis detects the time from the last blink to the first detected disruption of the tear film.
NIBUT is recorded in seconds.
Higher values indicate greater tear film stability and therefore a better outcome.
Measurements will be performed separately in the Lacrifill-treated eye and the contralateral sham-treated eye.
|
1 month; 3 months
|
|
Halo/glare size measured with the Real Artificial Lens Vision (RALV) system
Zeitfenster: 1 month and 3 months
|
Halo/glare size will be quantitatively assessed using the Real Artificial Lens Vision (RALV) halo/glare test.
Participants view a central white light source while optotypes are presented at decreasing radial distances from the light source.
Halo/glare size is recorded as angular extent in milliradians (mrad).
Higher values indicate a larger halo/glare phenomenon and therefore greater visual disturbance.
Measurements will be performed separately for the Lacrifill-treated eye and the contralateral sham-treated eye.
|
1 month and 3 months
|
|
Outcomes of questionnaires
Zeitfenster: 1 month; 3 months
|
Report of the dry eye disease questionnaires (OSDI and SPEED) and the National Eye Institute Visual function questionnaire 25 at month 1 and 3
|
1 month; 3 months
|
|
Number of applied artifical tear drops
Zeitfenster: 3 months
|
Self-reported number of average applications of artificial tear drops per eye per day.
|
3 months
|
|
Incidence of adverse events and device- or procedure-related adverse events
Zeitfenster: 3 months
|
Incidence, nature, severity, and relationship to the investigational device and/or procedure of adverse events, including serious adverse events and serious adverse device effects.
|
3 months
|
|
Inter-eye difference in visual quality assessment
Zeitfenster: 1 month; 3 months
|
Difference in Visual quality assessment measured by Refractive Artificial Lens Vision (RALV) at month 1 and 3
|
1 month; 3 months
|
Mitarbeiter und Ermittler
Sponsor
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn (Geschätzt)
Primärer Abschluss (Geschätzt)
Studienabschluss (Geschätzt)
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Tatsächlich)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Schlüsselwörter
Zusätzliche relevante MeSH-Bedingungen
Andere Studien-ID-Nummern
- 1058/2026
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Produkt, das in den USA hergestellt und aus den USA exportiert wird
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .